1
|
Allen JW, Vasireddy S, Kaufman J, Hughes JM, Sebelik M, Salazar JE, Niell HB. Feasibility study of capecitabine (cap) and cisplatin (cis) with radiation therapy (RT) in the management of patients with locally advanced unresectable squamous cell carcinoma of the head and neck (HNSCC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16520 Background: Concurrent chemoradiation has become the standard of care for locally advanced unresectable HNSCC. The most commonly used chemotherapy is cis and 5-fluorouracil (5-FU). We evaluated the feasibility of using cap and cis during RT in this population. Cap is an oral pro-drug of 5-FU that can be given daily with RT in order to enhance the activity of RT. Methods: Between Oct, 2003 and Sept, 2005, 12 male patients aged 46–83 were treated at the VA Medical Center. Patients received cis 100 mg/m2 on days 1 and 29 and cap 450 mg/m2 bid (2 hours prior to RT and 12 hours later) for 5 days of each week concurrent with RT to a total dose of 70 Gy in 35 fractions over 7 weeks. Primary endpoint of the study was toxicity. Results: All 12 patients were able to complete therapy. Treatment delays and/or dose modifications were needed in 7 patients. Treatment related toxicities included 6 patients with grade 3 mucositis and 5 patients with grade 3 dysphagia. Other grade 3 toxicities included 3 patients with dehydration and 1 patient each with leucopenia, constipation, nausea and vomiting, and odynophagia. Percutaneous gastrostomy (PEG) tubes were required in 5 patients. Complete response to chemoradiation was seen in 9 patients, 2 patients obtained partial response, and 1 patient progressed. Median progression free and overall survivals have not been reached with a median follow-up of 21 months. Conclusions: Cis and cap administered concurrently with RT has manageable toxicities and is active in patients with locally advanced unresectable HNSCC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. W. Allen
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - S. Vasireddy
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - J. Kaufman
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - J. M. Hughes
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - M. Sebelik
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - J. E. Salazar
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| | - H. B. Niell
- University of Tennessee Cancer Institute, Memphis, TN; VA Hospital, Memphis, TN
| |
Collapse
|